Dublin, Aug. 16, 2017 -- The "Antibody Target, Technology & Pipeline Database: 1-Year Subscription" newsletter has been added to Research and Markets' offering.
Subscription to this proprietary Antibody Database provides online access to information about more than 3,400 project entries for therapeutic antibodies on the market and in research & development.
Pre-established and free search functions allow to identify antibodies according to their:
- Technology (e.g. bispecifics, T-cell redirecting antibodies, antibody-drug conjugate, Fc-engineering, antibody format)
- Target (e.g. VEGF, immuen checkpoint modulators)
- Pipelines (selected by target, therapeutic area, company, technology)
- Sales (for marketed antibodies)
- R&D Phase (clinical phases, market, preclinical)
- Territory (countrywise)
- Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
- Drug Code/Name (for individual molecules)
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed.
Sales figures of major therapeutic antibodies on the market are provided. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
- T-cell Redirecting Antibodies
- Immune Checkpoint Modulating Antibodies
- Antibody-Drug Conjugates
- Bispecific Antibodies
- Oligo- and Polyclonal Antibodies
- Biosimilar Antibodies
Benefits from the Antibody Pipeline Database:
- Intuitive use
- Continuously updated (input from e.g. press releases, scientific meetings, company presentations)
- Designed for structured searches
- Focused on targets, technologies, therapeutic areas and R&D phases
- Ideal for competitor analysis (companies, targets, technologies, R&D phase)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
Project listing in a tabular format:
- Drug Codes
- Target
- Class of Compound
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
Therapeutic Areas:
- Cardiovascular & blood
- Dermatology
- Gastrointestinal
- Genitourinary, renal & gynecology
- Infectious & toxicology
- Metabolism & endocrine
- Neurology & psychiatry
- Oncology
- Ophthalmology & otorhinolaryngology
- Orthopedics, dental, anesthesia & surgery
- Pulmonary & respiratory
- Rheumatoid & autoimmune
Predefined Technologies of the Scroll-Down Menu - examples:
- T-Cell Redirecting Antibodies
- Antibody-Drug Conjugates per Payload (e.g. Auristatin, PBD)
- Bispecific Antibodies
- Oligo- and Polyclonal Antibodies
- In vitro generated Antibodies (phage display)
- Fab Antibodies
- Fc-Fusion Proteins
- Agonist Antibodies
- Transgenic Mouse Antibodies (e.g. XenoMouse, VelocImmune Mouse, KM Mouse)
- Human Cell-Derived Antibodies
Predefined Targets of the Scroll Down Menu - examples:
- Amyloid & Tau
- Antibody Sales in 2015
- Biosimilar Antibodies
- BCMA
- CD19
- CD20
- CD22
- CD30
- CD33
- CD37
- CD38
- CD40/-L
- CD123
- CEA
- CGRP
- EGF-R
- EpCAM
- FGF/-R
- GM-CSF
- Her2
- Interleukin-1/R
- Interleukin-6/R
- Interleukin-23 & 12/23
- Interleukin-4/-13
- Interleukin-17
- LAG-3
- Mesothelin
- OX40/-L
- PCSK9
- PSMA
- TIM-3
- TNF
For more information about this newsletter visit https://www.researchandmarkets.com/research/w3c2hq/antibody_target
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biotechnology


Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
OpenAI Explores Massive Funding Round at $750 Billion Valuation 



